analiza aiqbench
This paper presents a 22M-parameter vision transformer that predicts HER2 status from routine H&E pathology slides, aiming to give pathologists a baseline pre-read before costly in situ hybridisation. Its external validation is the most useful part for readers: AUC varies from 0.63 to 0.82 across three hospitals and drops on biopsies, and the authors report that per-lab normalisation and local fine-tuning help. The results are presented as research use only, not clinical validation.
A small HER2 reader for routine H&E slides: real-world deployment
arXiv:2610.40662v1 Announce Type: cross Abstract: HER2 status decides who receives HER2-targeted therapy. Pathologists score HER2 protein by immunohistochemistry (IHC); equivocal IHC 2+ tumours, their hardest calls, wait for in situ hybridisation (ISH). We built a HER2 reader for routine H&E slides, owned end to end, as a baseline for pathologists. A 22M-parameter ViT-S/16 tile encoder was trained on public TCGA slides by self-supervision, distillation from H-optimus-0 and two rounds of JEPA refinement; five cross-validated attention-based slide classifiers average their probabilities; and an operating point is fixed on training data. Compared under one paired ten-seed protocol, readers on our encoder rank first of 7 on external validation from TCGA-BRCA to Yale-HER2 (AUC 0.812), level with readers on encoders 4 and 50 times larger. We also rebuilt PathBench's encoder benchmark on public cohorts; our replica reproduces its published order of reference encoders, and under it our encoder ranks first of 7 on TCGA-BRCA (0.689) and sits level with H-optimus-0 and Phikon on Yale-HER2 (0.897). On three external hospitals our deployed reader reaches AUC 0.82 on Yale-HER2 (about 0.81 with training slides balanced for tissue size), 0.75 on HEROHE and 0.63 on BCNB biopsies, and among HEROHE's 85 IHC 2+ cases it ranks ISH-amplified above non-amplified tumours at 0.76, best among our TCGA-trained readers. Per-laboratory score normalisation and a laboratory's own slides improve it further on a new site. Without a GPU our reader needs 5-6 s per slide. It serves as a research-use pre-read in a pathology platform, where it proposes a probability and a call beside IHC and helps prioritise ISH for equivocal cases. Weights, per-slide predictions and the data behind every figure are public at https://huggingface.co/cloudkites/her2-reader.
Abstract:HER2 status decides who receives HER2-targeted therapy. Pathologists score HER2 protein by immunohistochemistry (IHC); equivocal IHC 2+ tumours, their hardest calls, wait for in situ hybridisation (ISH). We built a HER2 reader for routine H&E slides, owned end to end, as a baseline for pathologists. A 22M-parameter ViT-S/16 tile encoder was trained on public TCGA slides by self-supervision, distillation from H-optimus-0 and two rounds of JEPA refinement; five cross-validated attention-based slide classifiers average their probabilities; and an operating point is fixed on training data. Compared under one paired ten-seed protocol, readers on our encoder rank first of 7 on external validation from TCGA-BRCA to Yale-HER2 (AUC 0.812), level with readers on encoders 4 and 50 times larger. We also rebuilt PathBench's encoder benchmark on public cohorts; our replica reproduces its published order of reference encoders, and under it our encoder ranks first of 7 on TCGA-BRCA (0.689) and sits level with H-optimus-0 and Phikon on Yale-HER2 (0.897). On three external hospitals our deployed reader reaches AUC 0.82 on Yale-HER2 (about 0.81 with training slides balanced for tissue size), 0.75 on HEROHE and 0.63 on BCNB biopsies, and among HEROHE's 85 IHC 2+ cases it ranks ISH-amplified above non-amplified tumours at 0.76, best among our TCGA-trained readers. Per-laboratory score normalisation and a laboratory's own slides improve it further on a new site. Without a GPU our reader needs 5-6 s per slide. It serves as a research-use pre-read in a pathology platform, where it proposes a probability and a call beside IHC and helps prioritise ISH for equivocal cases. Weights, per-slide predictions and the data behind every figure are public at this https URL.
32 pages, 12 figures, 17 tables (including supplementary material). Research use only. Weights and data: this https URL
Quantitative Methods (q-bio.QM); Computer Vision and Pattern Recognition (cs.CV); Machine Learning (cs.LG); Software Engineering (cs.SE)
J.3; I.4.9; I.2.6
arXiv:2610.40662 [q-bio.QM]
(or arXiv:2610.40662v1 [q-bio.QM] for this version)
https://doi.org/10.48550/arXiv.2610.40662 Focus to learn more arXiv-issued DOI via DataCite
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Text integral sub licența deschisă a publicației · 398 cuvinte
Subiecte conexe
CT-VAM: A Cerebello-Thalamic-Inspired Vision-Action Model for Efficient Visuomotor Control
arXiv · 9 iun. 2026
TRW: TRACE-RealWorld---An Auditable Consistency Contract for World Models as Materialized Views
arXiv · 28 iul. 2026
SalQ-VLM: Fine-Grained Saliency-Guided Quantization for Vision-Language Models
arXiv · 22 sept. 2026